Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 122 of the 135 references it cites were found in a registry or an index; 84 of the 164 sources its claims cite were checked for support.

A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder

Open access
Celik, Muhammet, Gold, Mark S., Fuehrlein, Brian · 2024 · Brain Sciences

Abstract

Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies. While these advancements show potential, further research is crucial for a comprehensive understanding of their effectiveness. The clear shortage of approved medications and other treatment modalities underscores the pressing need for ongoing research. © 2024 by the authors.

Overview

CoChat Summary

## TL;DR

This narrative review surveys current and emerging treatments for alcohol withdrawal syndrome (AWS) and alcohol use disorder (AUD), emphasizing that benzodiazepines remain first-line for AWS while only three medications are FDA-approved for AUD: disulfiram, acamprosate, and naltrexone. It highlights promising but still emerging options, especially psychedelics with psychotherapy, noninvasive neural-circuit interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, while stressing that more clinical research is needed.

## Key findings

  • AUD is described as a major public health problem, contributing to over 140,000 annual deaths, over 200 related diseases and health conditions globally, and 5.1% of the global disease burden; the paper also states that only 7% of U.S. adults with AUD receive adequate treatment and only 16% of those treated achieve abstinence.
  • For AWS, benzodiazepines are the gold standard/first-line treatment; in one RCT of 198 patients, phenobarbital reduced ICU admissions from 25.0% to 8.0% versus placebo, and a meta-analysis of 12 studies/1,934 patients found no difference between phenobarbital and benzodiazepines on intubation, seizures, or hospital/ICU length of stay.
  • For AUD, the paper reports FDA-approved options as disulfiram, acamprosate, and naltrexone; a meta-analysis of 53 studies found the number needed to treat for naltrexone was 12 to prevent return to heavy drinking, and a meta-analysis of 24 RCTs (6,915 participants) found acamprosate reduced the risk of any drinking and increased cumulative abstinence.
  • Several emerging treatments showed promising signals: psilocybin plus psychotherapy produced a twofold reduction in heavy drinking with NNT 4.5 over 32 weeks; semaglutide case series reported a mean AUDIT score decrease of 9.5 points (p < 0.001) in 6 patients; and exenatide in an RCT of 127 participants did not reduce heavy drinking days overall but did reduce cue reactivity, with benefit in the subgroup with BMI > 30 kg/m².

## Methods

  • Narrative review based on an electronic literature search of PubMed, Google Scholar, Cochrane Library, and ClinicalTrials.gov.
  • Included clinical and animal trials, plus relevant systematic reviews, meta-analyses, and case reports published between 1 January 2013 and 1 January 2024; excluded editorials, expert opinions, and meeting abstracts.
  • Search terms covered alcohol, alcohol use disorder, alcohol withdrawal syndrome, alcohol dependence, alcohol consumption, relapse, anti-craving, and treatment-related terms; the review also provides brief historical/background context for each modality.

## Limitations

  • The paper explicitly notes that for several interventions, data are scarce or no recent clinical trials were identified (for example, ketamine for AWS, antipsychotics for AWS, GHB for AWS, CBT in recent AUD studies, PF-5190457, and others), so evidence is uneven across treatments.
  • The review states that further research is crucial and that many findings are promising but not yet definitive, especially for emerging modalities such as psychedelics, neural-circuit interventions, PDE-4 inhibitors, and GLP-1 agonists.
  • Evident from the text: this is a narrative review, not a systematic review or meta-analysis of its own, so the synthesis depends on heterogeneous prior studies and does not report a single pooled effect estimate across the full topic.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/brainsci14030294

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Alcohol’s effects on neurotransmitters and CNS.
Figure 1 Alcohol’s effects on neurotransmitters and CNS.CC BY · PubMed Central

Verification

Claims the paper makes

84 Valid · 2 Not valid · 76 Not checked · 16 Own results and interpretations

83 more claims · 46 with their cited sources checked

Create a free account to see all 178 claims and to verify the 6 references still open.

See all claims — free account
  • It may state two separate claims as one. 76
  • The quote only partly states this claim. 5
  • Probably not a substantial claim. 15

Create a free account to see these claims.

Citations

Cites

Show all 135 references

Research works printed but not linked: 1

  1. Kabat-Zinn, J. (2013). Full Catastrophe Living, Revised Edition: How to Cope with Stress, Pain and Illness Using Mindfulness Meditation, Hachette.

Cited by

See all 25

Metadata

Authors
Celik, M., Gold, M. S., & Fuehrlein, B.
Affiliations
  • New York Medical College (US)
  • Washington University in St. Louis (US)
  • Yale University (US)
Corresponding author
Gold, Mark S.
Venue
Brain Sciences
Publisher
MDPI AG
Published
2024-03-20
Volume
14
Issue
3
Pages
294
ISSN
2076-3425 (ISSN-L)
OpenAlex
W4392986055
Cited by
25
References
135
Citations by year
2026: 6 · 2025: 14 · 2024: 5
FWCI
1.64
Type
journal article
Language
en
Open access
Locations
  • Brain Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Touro Scholar (Touro College) (submittedVersion)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
  • Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
Keywords
alcoholism, alcohol withdrawal, pharmacotherapy, psychedelics, psychotherapy, phosphodiesterase-4 inhibitors, GLP-1 receptor agonists, treatment gap, disease burden

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. https://app.cochat.ai/papers/10.3390/brainsci14030294
The paper
Celik, M., Gold, M. S., & Fuehrlein, B. (2024). A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder. Brain Sciences. https://doi.org/10.3390/brainsci14030294

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.